Novel therapeutic strategies for targeting EGFR mutated non-small cell lung cancer

<p>Background: NSCLC patients with EGFR M+ tumours have marked clinical responses to EGFR-TKIs. Most patients experience tumour regrowth, as drug resistance emerges through on-target secondary EGFR-mutations or other activating mutations that reactivate the downstream signalling. However, a...